akavi 5mg Tablet

About

Ruxolitinib, the active ingredient in Jakavi (assuming 'akavi' is a typo for Jakavi), is a potent and selective Janus kinase (JAK1 and JAK2) inhibitor, primarily used in the treatment of myelofibrosis and polycythemia vera. These myeloproliferative neoplasms are characterized by dysregulated JAK-STAT signaling, leading to uncontrolled cell proliferation, splenomegaly, and debilitating constitutional symptoms. By inhibiting JAK1 and JAK2, ruxolitinib effectively reduces splenomegaly, improves disease-related symptoms such as fatigue, night sweats, and pruritus, and can improve overall survival in patients with myelofibrosis.

Its mechanism of action targets the underlying molecular pathology of these diseases, offering a significant therapeutic advance over conventional treatments. Ruxolitinib helps to normalize blood counts and reduce the inflammatory cytokine storm associated with these conditions, thereby improving patient quality of life and clinical outcomes.

Uses

• Treatment of intermediate or high-risk myelofibrosis.
• Management of polycythemia vera in patients resistant or intolerant to hydroxyurea.
• Reduction of splenomegaly in myelofibrosis and polycythemia vera.
• Alleviation of disease-related symptoms in myelofibrosis.

Directions For Use

Take this tablet orally, usually twice daily, with or without food. Follow your doctor's instructions carefully regarding dosage.

Benefits

• Significantly reduces spleen size in myelofibrosis and polycythemia vera.
• Alleviates debilitating symptoms like fatigue, itching, and night sweats.
• Improves quality of life for patients with myeloproliferative neoplasms.
• Can improve overall survival in patients with myelofibrosis.
• Targets the underlying JAK-STAT pathway dysregulation.
• Offers a targeted oral treatment option.

Side Effects

• Thrombocytopenia (low platelet count)
• Anemia (low red blood cell count)
• Neutropenia (low white blood cell count)
• Bruising
• Dizziness
• Headache
• Diarrhea
• Weight gain
• Fatigue
• Urinary tract infection
• Herpes zoster reactivation
• Elevated cholesterol levels

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to limit alcohol intake, especially if liver function is a concern.
• Pregnancy - Ruxolitinib is not recommended during pregnancy due to potential fetal harm. Women of childbearing potential should use effective contraception.
• Breastfeeding - It is advised to avoid breastfeeding during treatment with ruxolitinib and for a period after the last dose, due to potential excretion into breast milk.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments are often necessary, and liver function should be monitored regularly.
• Kidney - Dose adjustments are required for patients with moderate to severe renal impairment or end-stage renal disease. Renal function should be monitored.
• Lung - Monitor for new or worsening respiratory symptoms, as serious infections, including tuberculosis, can occur due to immunosuppression.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.